Home » Topics » Disease categories and therapies » Hematologic

Hematologic
RSS

Cor Therapeutics' NDA for Integrilin faces FDA review

June 7, 1996

Gea claims antiplatelet and fibrinolytic compounds

June 7, 1996

PharmaGenics discloses oligonucleotides

June 7, 1996

Thrombin inhibitors claimed by Boehringer Mannheim

May 31, 1996

Tirofiban advances through clinical trials; filing in sight

May 24, 1996

IND filing anticipated for TBC-1269

May 24, 1996

VCAM-1/VLA-4 inhibitors in the Texas Biotechnology pipeline

May 24, 1996

Fibrinogen antagonists claimed by Taisho

May 24, 1996

Mitsui Toatsu reports bicyclic fibrinogen antagonists

May 24, 1996

E. Merck claims oxazolidinone adhesion receptor antagonists

May 24, 1996

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for May 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for May 5, 2025.
CMS vows to put more emphasis on MA plans’ prior authorization
BioWorld MedTech
Physicians aren’t the only ones who see prior authorization (PA) practices as a significant problem, but John Brooks, deputy administrator at CMS, told a med tech...
100 days of uncertainty
BioWorld
The first 100 days of the Trump administration have been nothing short of chaotic, both in the U.S. and throughout the world. Shining a light through the...
Associate degree: PTC’s hints of phase II HD efficacy studied
BioWorld
PTC Therapeutics Inc. CEO Matthew Klein said the firm “achieved all we set out to [achieve] in phase II” with PTC-518 in Huntington’s disease (HD), but it wasn’t...